eligibility_summary
Include: Adults ≥18, ECOG 0–1, confirmed solid tumor with no SOC options, life expectancy >3 mo, adequate organs, expansion: ≥1 measurable lesion ≥10 mm not biopsied in last 3 mo. Exclude: untreated CNS mets, leptomeningeal disease, or spinal cord compression, other cancer <2 yrs, active infection, effusions/ascites, ILD, HIV/HBV/HCV, pneumonitis, recent anticancer tx/surgery/live vaccines, autoimmune on immunosuppression, unresolved ≥G2 tox, other trials, pregnancy/breastfeeding, no contraception.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: AMG 305, an investigational immunotherapy drug administered as a short-term IV infusion, tested as monotherapy. Mechanism of action: not disclosed in the trial listing, no specific molecular target, pathway, or modality (e.g., T‑cell engager, checkpoint inhibitor, cytokine) is specified. Cells/pathways targeted: not reported, the registry does not state the tumor antigen or immune pathway engaged by AMG 305. Study context: Phase 1 first-in-human dose escalation (Part A) and dose expansion (Part B) in adults with advanced solid tumors who have exhausted standard therapies, aiming to characterize safety, tolerability, pharmacokinetics, and to establish OBD/MTD and RP2D.